TOKYO & BASKING RIDGE, N.J., July 17, 2025--ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2+ Metastatic Breast Cancer ...

ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U.S. for the first-line treatment of adult patients with unresectable or ...

US FDA grants breakthrough therapy designation to Daiichi Sankyo & AstraZeneca’s Enhertu plus pertuzumab to treat unresectable or metastatic HER2 positive breast cancer Tokyo Friday, July 18, 2025, 14 ...

AstraZeneca reported 11% year-on-year revenue growth, excluding a 1% currency headwind, and core operating profit growth of 14%. Management reiterated its full-year guidance of high single-digit ...

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s prostate cancer was recently labelled “aggressive” and described ...

NSCLC driven by mutations in HER2 may be treated in the later lines with the HER2-targeted ADC trastuzumab deruxtecan (Enhertu; AstraZeneca/Daiichi Sankyo).

Home Investing Wellness Stocks to Invest in Now Breakthroughs that help us live longer, healthier lives can also create opportunities for investors.

AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R& ...